Skip to main content

Military Health System

DOD Pharmacy & Therapeutics Committee

The Department of Defense Pharmacy & Therapeutics (DOD P&T) Committee's mission is to uniformly, consistently, and equitably provide appropriate drug therapy to meet the clinical needs of DOD beneficiaries in an effective, efficient, and fiscally responsible manner.

To learn more, please see the Dec. 2004 Health Affairs Policy 04-032, TRICARE Pharmacy Benefit Formulary Management (clarified March 22, 2005).

DOD P&T Committee Meeting Schedule

View DOD P&T Meeting Minutes See Archived Meeting Pages


Feb. 8-9, 2023

Uniform Formulary Request for Quote Information (Class Nephrology Misc.)

  • UF BPA & UF ADP RFQ Documents Posted: Dec. 2, 2022
  • Pre-Proposal Teleconference: Dec. 7, 2022 at 1:00pm CT
  • UF BPA & UF ADP Class Quotes Due: Jan. 20, 2023 at 12:00pm CT

Uniform Formulary Request for Quote Information (Class Androgens Anabolic Steroids and Sleep Disorders)

  • UF BPA & UF ADP RFQ Documents Posted: Oct. 24, 2022
  • Pre-Proposal Teleconference: Nov. 9, 2022 at 1:00pm CT
  • UF BPA & UF ADP Class Quotes Due: Dec. 14, 2022 at 12:00pm CT

*Please note that all agents in the class, including brands and all generics, may be considered for formulary management actions. Additionally, if a drug is approved prior to Aug. 27, 2015, but not currently available the committee may still make a formulary recommendation.

Class Review Designated Newly Approved Drugs Drugs in Previously Reviewed Classes
  • ANDROGENS-ANABOLIC STEROIDS - TESTOSTERONE REPLACEMENT THERAPIES:
    • Androderm
    • Jatenzo
    • Kyzatrex 
    • Methitest 
    • Natesto
    • Testim
    • Testred
    • Tlando
    • Xyosted
  • SLEEP DISORDERS - DUAL OREXIN RECEPTOR ANTAGONISTS:
    • Belsomra
    • Dayvigo
    • Quviviq
  • NEPHROLOGY AGENTS MISCELLANEOUS – NA:
    • Tarpeyo
  • Auvelity

  • Basaglar Tempo Pen

  • Ermeza

  • Furoscix

  • Fylnetra

  • Humalog Tempo Pen

  • Leuprolide Depot

  • Lytgobi

  • Lyumjev Tempo Pen

  • Noxafil

  • Relyvrio

  • Rezlidhia

  • Xelstrym

 

 

 


If the DOD P&T Committee is unable to complete an evaluation of any of the drug classes, the Committee will continue its efforts at the next meeting.


Subject to Change Disclaimer

The Defense Health Agency (DHA) reserves the right to change the classes, sub-classes and/or designated new drugs, and other requirements, of whatever kind, affecting solicitations. The provisions of this table do not constitute a contract, express or implied, between the DHA and manufacturer or eligible bidder.

Last Updated: January 19, 2023
Follow us on Instagram Follow us on LinkedIn Follow us on Facebook Follow us on Twitter Follow us on YouTube Sign up on GovDelivery